• Revenue up 8.3% to $79.5m
• EBITDA down 0.1% to $12.4m
• Net profit after tax down 3.3% to $8.8m
• Fully franked dividend of 10.0 cents per share

Vita Life Sciences Ltd reported a strong financial performance for the 2024 financial year, with revenue increasing by 8.3% to $79.5m. The company's EBITDA was down slightly by 0.1% to $12.4m, while net profit after tax declined by 3.3% to $8.8m. The Group's net assets increased by 21% to $52.3m, including cash of $28.6m, and the company remained debt-free. The Group generated record revenue in Australia, up 4% to $44.4m, and in Malaysia, up 12% to $25.7m. Singapore also saw a 21% increase in revenue to $7.6m. The company's dividend for FY 2024 is 10.0 cents per share fully franked, the 15th consecutive year of dividend payments to shareholders. Overall trading conditions remain positive as the company heads into 2025.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics.

The company stated that overall trading conditions remain positive as it heads further into 2025, reflecting the resilience of its strategy and market positioning.